Genentech will make use of Vernalis’ fragment and structure-based drug discovery platform against an undisclosed target.
Vernalis CEO Ian Garland said the company is happy that Genentech chose them to work on the concerned target.
"Their selection of Vernalis further endorses our market leading fragment and structure-based drug discovery platform and validates our strategy to substantially fund our research activities through collaborations," Garland added.
The financial terms of this collaboration have not been revealed.
Â